NeuroScientific widens chronic bowel disease stem cell therapy program

NeuroScientific Biopharmaceuticals has dosed a fourth Crohn’s disease patient with its StemSmart stem-cell therapy, in a step towards phase two trials of a novel treatment for the debilitating bowel condition.